July 20, 2024

5 Steps to Reliable Metagenomic Data Analysis

Metagenomic data analysis remains one of the most error-prone steps in the metagenomic next-generation sequencing (mNGS) workflow. A landmark 2023 paper in Cancer Cell titled “Major Data Analysis Errors Invalidate Cancer Microbiome Findings” demonstrated that the same sequencing dataset can yield completely opposite conclusions depending on the reference database and computational methods used. The original study had analyzed over 10,000 samples across 33 cancer types for non-human reads, deriving an AI algorithm that claimed to classify cancer type with high accuracy. Upon re-analysis, the findings were completely overturned. For lab managers evaluating mNGS bioinformatics pipelines, this case illustrates why database quality and analytical rigor are non-negotiable.

Watch the full webinar:

Key Takeaways

Reference genome databases contaminated with human sequences generate millions of false-positive bacterial classifications in mNGS workflows
Contamination in mNGS is both physical (sample, reagents, environment) and bioinformatic (database errors, taxonomic misassignment)
Integrated pipelines with curated databases and workflow-specific QC outperform standalone analysis tools built on large public databases for clinical pathogen identification
Cloud-based deployment with regional data residency meets GDPR and HIPAA requirements for clinical mNGS
A complete mNGS solution must address contamination at every stage, from sample processing through bioinformatic analysis

How Database Contamination Invalidates mNGS Results

The core problem is straightforward: many bacterial reference genomes in public databases are contaminated with human sequences. When mNGS reads from human clinical samples are mapped against these contaminated references, human reads are misclassified as bacterial. This is especially damaging in clinical mNGS, where microbial DNA represents a tiny fraction of total sequencing output. Even a small percentage of misclassified human reads can overwhelm the genuine microbial signal.

This issue has been repeatedly documented across multiple clinical contexts. Studies claiming to identify unique microbiomes in human placenta and whole blood have been overturned upon re-analysis with cleaner reference databases. The pattern is consistent: when the bioinformatic foundation is flawed, downstream conclusions collapse regardless of how rigorous the wet-lab work was.

For clinical laboratories considering mNGS adoption, database quality should be evaluated with the same rigor as reagent quality. A pipeline built on contaminated references will produce unreliable results no matter how sensitive the sequencing platform.

Sources of Contamination Across the mNGS Workflow

A recent study identified the key contamination sources in mNGS workflows, confirming that contamination in mNGS is not a single-point failure. It accumulates across the entire workflow through four distinct mechanisms:

Sample-level contamination. Human clinical samples contain overwhelming host DNA. In whole blood, microbial DNA may represent less than 0.1% of total nucleic acid content. Without pre-analytical host depletion, the vast majority of sequencing reads are wasted on host genome.
Reagent contamination. Extraction buffers, library preparation enzymes, and other consumables inevitably contain trace microbial DNA. These reagent-derived reads are indistinguishable from true sample reads without proper controls and background subtraction.
Cross-contamination during multiplexing. When samples are pooled for sequencing, index hopping and demultiplexing errors can transfer reads between samples. This is particularly problematic for low-biomass samples where even a few misassigned reads can appear as a positive detection.
Bioinformatic contamination. Errors in reference databases, incorrect taxonomic assignments, and inappropriate mapping parameters generate false positives during data analysis. Unlike physical contamination, bioinformatic contamination affects every sample analyzed through the pipeline.

Addressing only one contamination source while ignoring others produces incomplete results. A reliable mNGS workflow must implement controls and mitigation strategies at each stage.

Building High-Fidelity Reference Databases for Pathogen Identification

The difference between an integrated clinical-grade mNGS pipeline and a standalone tool built on a general-purpose public database lies in curation depth, QC, and workflow context. A high-fidelity pathogen database requires several specific quality measures.

Key Features of a Curated mNGS Database

Completeness verification. State-of-the-art QC algorithms confirm that each reference genome in the database is complete and free of contaminating sequences from other organisms, including human.
Taxonomic accuracy. Continuous curation of taxonomic assignments corrects the misannotations that are common in public databases. Species that have been reclassified, merged, or split must be updated to reflect current nomenclature.
Homology benchmarking. Microbes with unusual sequence homologies or close taxonomic relationships require special handling. Without proper benchmarking, reads from one species can be incorrectly assigned to a closely related organism.
Clinical validation. Testing against clinical samples with known pathogen content provides ground-truth validation that synthetic benchmarks cannot replicate. Tracking discrepancies between expected and observed results identifies misannotated or misrepresented species in the database.

A curated database of 1,400+ validated pathogen references, tested against real clinical samples, provides more reliable results than an uncurated database of 100,000+ genomes that includes contaminated and misannotated entries.

Secure Cloud-Based Deployment for Clinical Genomics

Clinical mNGS generates large datasets that require scalable compute infrastructure. Cloud-based deployment through platforms like Amazon Web Services (AWS) provides several advantages for clinical laboratories:

Scalability. Whole genome and metagenomic analyses routinely involve 200-300 GB of input data. Cloud infrastructure handles these workloads without local hardware investment.
Data residency compliance. Clinical data regulations vary by jurisdiction. AWS operates in more than eight global regions, enabling laboratories to guarantee that patient data never leaves the required geographic boundaries. This meets both GDPR (European) and HIPAA (US) requirements.
Operational simplicity. Bioinformatics scientists should not need to manage servers. A cloud-based platform abstracts infrastructure management so that analysis pipelines can be run with minimal training, typically in minutes rather than days.

For clinical applications, the target is to complete per-sample analysis within 30 minutes, including QC checks, host read removal, pathogen mapping, and report generation.

How PaRTI-Seq Analysis Addresses Bioinformatic Contamination

Micronbrane Medical’s PaRTI-Seq Analysis pipeline was developed specifically to close the bioinformatic gap in the mNGS workflow. Combined with the Devin Host Depletion Filter for physical host removal and mNGS-grade reagents for extraction and library construction, PaRTI-Seq Analysis tackles the bioinformatic contamination that persists after wet-lab optimization. The positioning is important: PaRTI-Seq is an integrated sample-to-analysis pipeline with curated references and QC, not a standalone classifier pointed at public, uncurated databases.

The pipeline uses BWA mapping against a curated database of over 1,400 pathogens, with mapping parameters specifically validated for low-biomass human clinical samples. The research-use-only (RUO) version provides a spreadsheet of mapped reads to all pathogens in the database, which laboratories can use as a complementary cross-check against their existing analysis tools.

The clinical application, currently in development, will implement validated cutoff values to automatically distinguish true positives from background noise and generate clinical reports. This addresses the final challenge in clinical mNGS adoption: providing actionable, interpretable results without requiring bioinformatics expertise at the point of care.

About the Speaker

Mengchu Wu, PhD — Co-founder, CEO, and Chairwoman, Micronbrane Medical Amit Sinha, PhD — Founder and CEO, Basepair